Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
630 stopped studies mapped to Malignant Hepatobiliary Neoplasm and descendants · 92% state a reason
Over the 630 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06361758 | Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC | Phase 2 | withdrawn | Apr 12, 2024 | Shanghai Zhongshan Hospital | The PI has initiated a global multicenter Phase II clinical trial in the same direction, conducted… | Other (stated, no rule matched) |
| NCT03534141 | Mild Hypothermia and Acute Kidney Injury in Liver Transplantation(MHALT) | N/A | terminated | May 23, 2018 | University of California, San Francisco | Terminated 9/24/23 at 85% target enrollment due to slow accrual of subjects. The decline in… | Enrollment / accrual |
| NCT02807181 | SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line…(SIRCCA) | Phase 2 / Phase 3 | terminated | Jun 21, 2016 | Sirtex Medical | Slow enrollment | Enrollment / accrual |
| NCT04732286 | A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With… | Phase 3 | terminated | Feb 1, 2021 | Hoffmann-La Roche | The study was completed as pre-specified in the protocol. Study was terminated only for… | Other (stated, no rule matched) |
| NCT05242822 | A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or… | Phase 1 | terminated | Feb 16, 2022 | Kinnate Biopharma | Due to a change in the Sponsor's corporate strategy the study was terminated early by the Sponsor… | Enrollment / accrual |
| NCT05757492 | Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients… | Phase 1 | terminated | Mar 7, 2023 | Coherus Oncology, Inc. | The study was terminated for strategic reasons (not for safety concerns) | Safety / toxicity |
| NCT02939807 | A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular… | Phase 2 | withdrawn | Oct 20, 2016 | Medical University of South Carolina | study is being rewritten for different disease population | Other (stated, no rule matched) |
| NCT05448677 | Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First…(ABE-LIVER) | Phase 2 | terminated | Jul 7, 2022 | University Hospital, Grenoble | Study terminated due to recruitement issues | Enrollment / accrual |
| NCT05565794 | Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements | Phase 2 | terminated | Oct 4, 2022 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | slow recruitment | Enrollment / accrual |
| NCT04383210 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid… | Phase 2 | terminated | May 12, 2020 | Elevation Oncology | Business decision | Sponsor / business decision |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab… | Phase 1 / Phase 2 | terminated | Feb 4, 2019 | Kymab Limited | Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Safety / toxicity |
| NCT03636607 | Diagnostic Significance of Single Center, Open and Prospective Evaluation of… | N/A | withdrawn | Aug 17, 2018 | Fifth Affiliated Hospital, Sun Yat-Sen University | No participents enrolled | Enrollment / accrual |
| NCT03889093 | Radioembolization of Primary and Secondary Liver Malignancies and The Effect On The… | N/A | terminated | Mar 26, 2019 | University of Minnesota | PI Left Institution | Investigator |
| NCT04866836 | A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of… | Phase 2 | terminated | Apr 30, 2021 | The First Affiliated Hospital with Nanjing Medical University | The study was prematurely terminated due to difficulties in recruitment. | Enrollment / accrual |
| NCT04976660 | TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors | Phase 1 / Phase 2 | withdrawn | Jul 26, 2021 | Tarus Therapeutics, Inc. | Tarus is conducting clinical development under a single IND, specifically IND for TT-10 (PORT-6).… | Other (stated, no rule matched) |
| NCT06144827 | A Pilot Study For Patients Receiving Radiation Therapy for Liver Cancer(HepQuant) | N/A | withdrawn | Nov 22, 2023 | Montefiore Medical Center | PI indicated that the site was unable to procure shunt. No participants were enrolled and this… | Enrollment / accrual |
| NCT04629339 | Study of INCB086550 in Select Solid Tumors | Phase 2 | terminated | Nov 16, 2020 | Incyte Corporation | Strategic business decision to terminate the study effective immediately. This is due to a company… | Sponsor / business decision |
| NCT05137899 | Neoadjuvant Combination of Atezolizumab/Bevacizumab Versus Neoadjuvant Radiation Therapy(ADVANCE HCC) | Phase 2 | terminated | Nov 30, 2021 | Ontario Clinical Oncology Group (OCOG) | Recruitment challenges, Hoffman La Roche strategic priority shift | Enrollment / accrual |
| NCT05770882 | Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | terminated | Mar 16, 2023 | Great Novel Therapeutics Biotech & Medicals Corporation | The overall profile does not support development for Hepatocellular Carcinoma | Other (stated, no rule matched) |
| NCT03812289 | Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer | N/A | terminated | Jan 23, 2019 | OHSU Knight Cancer Institute | PI decision | Other (stated, no rule matched) |
| NCT06848556 | Evaluate the Effect of Tirazamine on Primary Liver Cancer. | Phase 1 / Phase 2 | terminated | Feb 27, 2025 | Zhejiang Raygene Pharmaceuticals Co., Ltd | Company Operational Strategy Adjustment | Sponsor / business decision |
| NCT04268888 | Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC(TACE-3) | Phase 2 / Phase 3 | suspended | Feb 13, 2020 | The Clatterbridge Cancer Centre NHS Foundation Trust | Analysis meant the study should close to recruitment | Enrollment / accrual |
| NCT04709380 | Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced… | Phase 3 | terminated | Jan 14, 2021 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | IDMC recommended to terminate the study since Interim analysis showed that the experimental group… | Efficacy / futility |
| NCT05909995 | Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid… | Phase 1 | terminated | Jun 18, 2023 | Incyte Corporation | This was a strategic business decision. There were no safety concerns contributing to this decision. | Safety / toxicity |
| NCT01205828 | ABT-888 and Temozolomide for Liver Cancer | Phase 2 | terminated | Sep 21, 2010 | Georgetown University | Lack of efficacy | Efficacy / futility |
| NCT02935478 | Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver… | N/A | suspended | Oct 17, 2016 | St. Louis University | IRB reviewing study conduct and adverse events | Safety / toxicity |
| NCT02853500 | Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy… | Phase 4 | withdrawn | Aug 3, 2016 | Dana-Farber Cancer Institute | No participants enrolled. Inability to perform intraprocedural MRI with the intraarterial infusion… | Enrollment / accrual |
| NCT05497453 | A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and…(MYCHELANGELO I) | Phase 1 / Phase 2 | terminated | Aug 11, 2022 | Omega Therapeutics | Sponsor decision to terminate after monotherapy dose escalation. | Sponsor / business decision |
| NCT05845502 | Single-arm, Open-label Clinical Study of SZ003 in the Treatment of Advanced… | N/A | terminated | May 6, 2023 | Shantou University Medical College | Failed to recruit more volunteers | Enrollment / accrual |
| NCT05776875 | Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC | Phase 2 | terminated | Mar 20, 2023 | Yale University | Low enrollment | Enrollment / accrual |
| NCT04066660 | Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC) | N/A | terminated | Aug 26, 2019 | Hi-Q Marine Biotech International, Ltd. | After interim analysis, we planned to recruit 100 participants. However, due to COVID-19… | COVID-19 / pandemic |
| NCT05653427 | A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced… | Phase 2 | terminated | Dec 16, 2022 | Janssen Research & Development, LLC | N\~15 subjects data analysis did not meet statistical consideration of ORR and study… | Efficacy / futility |
| NCT05717400 | Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma… | Phase 4 | terminated | Feb 8, 2023 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT02878473 | Liver Transplantation for Early Intrahepatic Cholangiocarcinoma(LT for iCCA) | Phase 2 | terminated | Aug 25, 2016 | University Health Network, Toronto | Low accrual | Enrollment / accrual |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT05418387 | A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer… | N/A | withdrawn | Jun 14, 2022 | University of Arizona | The study will be withdrawn as the Principal Investigator, Ken Batai, left the institution prior to… | Investigator |
| NCT03145558 | TATE Versus TACE in Intermediate Stage HCC(TATE) | Phase 2 | terminated | May 9, 2017 | Teclison Ltd. | Landscape changed and the study population is no longer suitable for the study treatment. | Other (stated, no rule matched) |
| NCT01101906 | A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients… | Phase 2 | terminated | Apr 12, 2010 | Astellas Pharma Inc | Company decided not to pursue the development of this drug in this patient population at this time | Sponsor / business decision |
| NCT02512692 | Gemcitabine-Cisplatin-90Y TARE for Unresectable Intrahepatic Cholangiocarcinoma | N/A | terminated | Jul 31, 2015 | Medical University of South Carolina | Enrollment closed by internal scientific review committee due to slow accrual. | Enrollment / accrual |
| NCT06017297 | Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma(ESR-22-21719) | Phase 2 | withdrawn | Aug 30, 2023 | Georgetown University | Sponsor decision and challenges in finding eligible participants | Sponsor / business decision |
| NCT04989218 | Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic…(ICC) | Phase 1 / Phase 2 | terminated | Aug 4, 2021 | University of Alabama at Birmingham | Slow accrual and study sponsor decision. | Enrollment / accrual |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With… | Phase 1 | terminated | Sep 13, 2023 | Molecular Templates, Inc. | Sponsor Termination | Other (stated, no rule matched) |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | Phase 2 | terminated | Aug 19, 2021 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT04923672 | Exercise Preconditioning with Cancer Surgeries(ExPre 01) | N/A | terminated | Jun 11, 2021 | University of Virginia | Company providing the computer application for exercise intervention suddenly closed for business | Sponsor / business decision |
| NCT06199882 | SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma | Phase 2 | suspended | Jan 10, 2024 | Zhejiang Cancer Hospital | Patient recruitment difficulties | Enrollment / accrual |
| NCT04003896 | A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma | Phase 2 | terminated | Jul 1, 2019 | Milton S. Hershey Medical Center | The manufacturer and funder Eli Lilly requested to terminate the study | Drug supply |
| NCT04683939 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in… | Phase 1 / Phase 2 | terminated | Dec 24, 2020 | BioNTech SE | Sponsor decision | Sponsor / business decision |
| NCT00667628 | Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE)… | Phase 2 | terminated | Apr 28, 2008 | Taiho Oncology, Inc. | Terminated due to safety concerns. | Safety / toxicity |
| NCT00687596 | Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular… | Phase 2 | terminated | Jun 2, 2008 | Taiho Oncology, Inc. | Terminated due to safety concerns | Safety / toxicity |
| NCT00756782 | A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With… | Phase 2 | withdrawn | Sep 22, 2008 | Taiho Oncology, Inc. | Terminated due to safety concerns. | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 23, 2025source: clinicaltrials